595 followers
RT @JRheumatology: 🧊 Raynaud’s in SSc — real world • US community cohort n=270 (1999–2023) • 61% ever treated; persistence 29% • CCBs first…
RT @JRheumatology: 🧊 Raynaud’s in SSc — real world • US community cohort n=270 (1999–2023) • 61% ever treated; persistence 29% • CCBs first…
RT @JRheumatology: 🧊 Raynaud’s in SSc — real world • US community cohort n=270 (1999–2023) • 61% ever treated; persistence 29% • CCBs first…
🧊 Raynaud’s in SSc — real world • US community cohort n=270 (1999–2023) • 61% ever treated; persistence 29% • CCBs first-line; ↑PDE5i since 2019 • Starts linked to HTN, lung dz, immunRx, income & insurance Dive in 🔗 #Scleroderma #Raynauds https://t…
RT @JRheumatology: 🧊 How is Raynaud managed in US SSc patients? 📊 From 270 patients: • Only 61% received RP meds • CCBs most common (48%)…